Aegis Therapeutics Invited to Present at the Health Care Ventures 2005 Conference.SAN DIEGO -- Aegis Therapeutics LLC (Logical Link Control) See "LANs" under data link protocol.
LLC - Logical Link Control will be presenting at the Health Care Ventures 2005 Conference, sponsored by Dow Jones VentureWire. Dr. Edward T. Maggio, Ph.D., President and Chief Executive Officer, will provide a corporate overview, including a review of the Company's patented Intravail(TM) technology for intranasal in·tra·na·sal
Within the nose. and transmucosal delivery of peptide, protein, and non-protein macromolecular mac·ro·mol·e·cule
A very large molecule, such as a polymer or protein, consisting of many smaller structural units linked together. Also called supermolecule. therapeutics, on Wednesday, Sept. 28 at 9:45 AM at the Sofitel San Francisco Bay San Francisco Bay, 50 mi (80 km) long and from 3 to 13 mi (4.8–21 km) wide, W Calif.; entered through the Golden Gate, a strait between two peninsulas. , Redwood City, CA.
The conference will include CEOs from 60 companies in the most competitive sectors -- including diabetes, obesity, oncology, neurology, personalized medicine, orthopedics, and eye disorders. Additional information on the conference may be found on the internet at the conference website: http://healthcare-ventures.net/default.asp.
About Aegis Therapeutics
Aegis Therapeutics LLC is a specialty pharmaceutical company commercializing its patented Intravail(TM) drug delivery technology that enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis' Intravail(TM) absorption enhancement agents are mild and non-irritating to mucosal membranes. They provide exceptionally high and unmatched bioavailability bioavailability /bio·avail·a·bil·i·ty/ (bi?o-ah-val?ah-bil´i-te) the degree to which a drug or other substance becomes available to the target tissue after administration.
n. performance, comparable in efficiency to subcutaneous injection, via the intranasal and other mucosal membrane administration routes. Intravail(TM) also provides for rapid drug absorption and onset of action onset of action Pharmacology The length of time needed for a medicine to become effective. See Therapeutic drug monitoring. , controlled transient permeation of the nasal mucosal barrier, avoidance of gastric hydrolysis hydrolysis (hīdrŏl`ĭsĭs), chemical reaction of a compound with water, usually resulting in the formation of one or more new compounds. and "first pass effect" elimination by the liver, greater patient convenience and compliance, elimination of needle-stick injuries and associated transmission of blood borne pathogens, compatibility with current nasal delivery devices, and ease of formulation, scale-up, and production. For more information about Aegis, please visit the Aegis website at: http://www.aegisthera.com.